Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners.

Saskia Van der Meer, Boudewijn J Kollen, Willem H Hirdes, Martijn G Steffens, Josette E H M Hoekstra-Weebers, Rien M Nijman, Marco H Blanker

July 2013 BJU Int

Synopsis of Social media discussions

The collective discussions emphasize the study's influence on PSA testing, using clear language such as 'impact' and 'detection,' which indicates recognition of its importance. The tone is generally factual but acknowledges concerns about reduced follow-up care, illustrating how word choice and focus on screening outcomes signal both acknowledgment and concern over clinical practices.

A
Agreement
 Strong agreement

Most posts acknowledge the study's findings, reflecting a strong consensus that the ERSPC has influenced PSA testing behaviors.

I
Interest
 Moderate level of interest

While the discussion shows moderate interest, it largely focuses on reporting the study's results rather than exploring broader implications.

E
Engagement
 Moderate level of engagement

Participants demonstrate some engagement by referencing the study's key findings and potential clinical impacts, though there is limited in-depth debate.

I
Impact
 High level of impact

The posts suggest the study has significant implications for prostate cancer screening practices, highlighting shifts in testing and follow-up.

Social Mentions

YouTube

1 Videos

Twitter

6 Posts

Blogs

2 Articles

News

2 Articles

Metrics

Video Views

317

Extended Reach

19,012

Social Features

11

Timeline: Posts about article

Top Social Media Posts

Posts referencing the article

Impact of ERSPC Study on PSA Testing by Dutch General Practitioners

Impact of ERSPC Study on PSA Testing by Dutch General Practitioners

The study examined how the 2009 ERSPC trial influenced PSA testing habits among Dutch GPs, showing a decline in initial and follow-up tests, especially four months after publication, mainly in men aged 60. This may affect prostate cancer detection and follow-up care.

BJUI

June 27, 2013

317 views

  • EurekaMag
    @EurekaMag (Twitter)

    Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners https://t.co/xXKfDyCcwb
    view full post

    February 26, 2025

  • EurekaMag
    @EurekaMag (Twitter)

    Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners https://t.co/xXKfDyBEGD
    view full post

    February 18, 2025

  • Documents Delivered, LLC
    @DocsDel (Twitter)

    Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) https://t.co/Q7ALGEsYKe
    view full post

    October 21, 2024

  • amnatacharoen
    @amnatacharoen (Twitter)

    RT @DocsDel: Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) https://t.c…
    view full post

    November 16, 2023

    2

  • POPLINE
    @POPLINE_org (Twitter)

    RT @DocsDel: Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) https://t.c…
    view full post

    November 16, 2023

    2

  • Documents Delivered, LLC
    @DocsDel (Twitter)

    Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) https://t.co/PqsPKDL5FI
    view full post

    November 16, 2023

    2

Abstract Synopsis

  • The study examined how the 2009 ERSPC study about prostate cancer screening affected PSA testing habits among Dutch general practitioners, showing a decrease in initial and follow-up tests, especially four months after publication, mainly in men aged 60.
  • Both primary PSA testing and follow-up testing declined after the ERSPC publication, with fewer tests for levels below and above specific thresholds (4ng/mL and 10ng/mL), and a slight reduction in referrals to urologists, indicating a possible reduction in prostate cancer detection efforts.
  • The decrease in follow-up testing after abnormal PSA results suggests that patients may not be getting enough subsequent testing to monitor potential issues, but the reasons for this decrease are still unclear, raising concerns about the adequacy of prostate cancer screening and follow-up care post-ERSPC.]